MLTX vs SGP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MLTX · MoonLake Immunotherapeutics$11.07 ▲ 0.36%
SGP · SpyGlass Pharma$30.43 ▼ 1.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MLTX -28.6%
- SGP +15.3%
Head to head
| Metric | MLTX | SGP |
|---|---|---|
| Price | $11.07 | $30.43 |
| Change today | ▲ 0.36% | ▼ 1.14% |
| Market cap | $942.13M | $1.02B |
| Return, 3 months | -28.0% | +15.9% |
| Return, year to date | -16.0% | – |
| Return, 1 year | -12.6% | – |
| P/E (TTM) | – | – |
| P/B | 2.5 | 4.8 |
| P/E percentile vs own 5y | 87th | 55th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -12.5% | -147.1% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -81.6% | -114.4% |
| Analyst target vs. price | +221.3% | +44.6% |
| Analyst buy share | 88% | 100% |
| RSI (14) | 44 | 47 |
| 30-day volatility | 80.9% | 66.7% |
| Max drawdown, 1 year | -56.9% | -40.8% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SGP is the largest of the group by market value.
- SGP has been the calmest stock over the last 30 days.